Hyperbaric oxygen therapy restores tissue oxygenation and accelerates healing in pressure ulcers and decubitus wounds
Hyperbaric oxygen therapy restores tissue oxygenation and accelerates healing in pressure ulcers and decubitus wounds
Understanding pressure ulcers and how HBOT restores tissue oxygenation to support healing
Pressure ulcers — also called pressure injuries, decubitus ulcers or bedsores — are localized injuries to skin and underlying tissue that develop when sustained pressure compresses blood vessels and deprives tissue of oxygen. They are among the most common and costly complications of immobility, affecting approximately 2.5 million Americans each year and accounting for substantial morbidity, mortality and healthcare costs.
Pressure ulcers are staged by depth of tissue involvement. Stage 1 (non-blanchable redness) and Stage 2 (partial thickness skin loss) wounds typically heal with appropriate pressure relief and wound care. Stage 3 (full thickness skin loss extending to but not including bone, tendon or muscle) and Stage 4 (full thickness tissue loss with exposed or palpable bone, tendon or muscle) wounds are far more serious — they carry a high risk of infection, osteomyelitis, sepsis and even death, and they frequently fail to heal despite optimal conventional wound care.
Patients at highest risk for pressure ulcers include those with spinal cord injury (who have impaired mobility, sensation and circulation), elderly patients in nursing facilities and hospitals, and critically ill ICU patients who cannot be adequately repositioned. In these populations, pressure ulcers often develop despite preventive measures and, once established, prove extremely difficult to heal because the same physiological factors that caused the ulcer — impaired mobility, poor nutrition, compromised circulation and neurological dysfunction — continue to impair healing.
HBOT addresses the tissue-level mechanism of pressure ulcer failure: tissue hypoxia. By delivering dissolved oxygen to the ischemic wound bed and surrounding tissue via plasma diffusion, HBOT restores the oxygen required for fibroblast activity, collagen synthesis, angiogenesis and neutrophil killing. Concurrently, HBOT stimulates the growth of new capillaries in damaged peri-wound tissue, progressively improving the wound’s vascular supply. Multiple controlled studies and Medicare coverage guidelines support HBOT for qualifying Stage 3 and 4 pressure wounds.
Full thickness skin loss with wound base extending into subcutaneous fat (Stage 3) or to bone, tendon or muscle (Stage 4)
Wound that fails to show measurable progress after 4 or more weeks of appropriate wound care
Signs of wound infection — increased exudate, odor, erythema, warmth or elevated inflammatory markers
Osteomyelitis (bone infection) underlying the wound, particularly over the sacrum, ischium or heel
Significant pain associated with wound care and position changes
Wound recurrence after previous closure, particularly in patients with ongoing immobility
How HBOT breaks the ischemia-hypoxia cycle preventing pressure ulcer healing
Pressure ulcers create a self-perpetuating cycle of ischemia, hypoxia, immune failure and infection. HBOT addresses every element of this cycle simultaneously.
Restores oxygen to the ischemic wound bed
Stimulates new blood vessel growth in devascularized tissue
Reconstitutes immune cell killing power in infected wounds
Accelerates granulation tissue formation and wound closure
Reduces wound-related pain and systemic inflammatory burden
Supports skin graft take in surgically managed pressure wounds
For Providers
Clinical evidence for HBOT in pressure ulcers and decubitus wounds
HBOT for pressure ulcers is supported by controlled clinical trials, Cochrane systematic review evidence, and Medicare coverage recognition under the non-healing wound indication.
Heng et al. — controlled trial in chronic pressure ulcers (2000): A controlled study of HBOT in chronic pressure ulcers published in Wound Repair and Regeneration demonstrated that HBOT significantly accelerated wound area reduction and achieved higher rates of complete wound closure compared to standard wound care alone. The HBOT group also showed significantly better granulation tissue quality on wound bed assessment, reflecting improved cellular healing capacity. [Heng MCY et al. Wound Repair Regen. 2000;8(5):332–339. PMID: 11186097]
Kranke et al. — Cochrane systematic review (2012): The Cochrane review of HBOT for chronic wounds, covering 12 randomized trials across multiple wound types, found evidence supporting HBOT for accelerating wound healing compared to standard care, with the strongest evidence in populations with ischemic and hypoxic wounds. The review supported HBOT as a clinically meaningful adjunct for wounds failing standard care, consistent with the Medicare coverage framework for qualifying non-healing wounds. [Kranke P et al. Cochrane Database Syst Rev. 2012;4:CD004123. PMID: 22513920]
Pressure ulcer osteomyelitis — the antibiotic synergy mechanism: When pressure ulcers penetrate to bone, the resulting osteomyelitis is particularly difficult to treat with antibiotics alone because hypoxic bone tissue severely impairs antibiotic penetration and neutrophil function. HBOT addresses both impediments simultaneously: raising bone tissue oxygen to levels that restore neutrophil killing and significantly improve antibiotic activity in infected bone tissue. Chronic refractory osteomyelitis is a Medicare-approved HBOT indication, and the evidence for HBOT in osteomyelitis directly applies to pressure ulcer-associated bone infection. [Davis JC et al. J Bone Joint Surg Am. 1986;68(8):1210–1217. PMID: 3771601]
Transcutaneous oximetry as a predictor: In pressure ulcers as in other ischemic wounds, transcutaneous oxygen tension (TcPO2) measured at the peri-wound skin during HBOT is the most reliable predictor of healing response. Wounds achieving TcPO2 above 200 mmHg during HBOT consistently show better healing outcomes, providing both an objective basis for patient selection and a real-time measure of treatment adequacy. We use TcPO2 monitoring in our pressure ulcer patients to confirm that treatment oxygen is reaching therapeutic levels.
Our pressure ulcer HBOT protocol at Bay Area Hyperbarics
HBOT for pressure ulcers is most effective when used alongside comprehensive pressure ulcer care: optimized pressure relief and repositioning, nutritional support, appropriate wound dressings and infection management. HBOT addresses the tissue-level oxygen deficit; the full treatment environment addresses the systemic and mechanical factors sustaining the wound.
Wound assessment and care team coordination
Our medical team reviews your pressure ulcer stage, size, depth, wound bed characteristics, bacterial burden, underlying risk factors (spinal cord injury, immobility, malnutrition, diabetes) and prior wound care. We coordinate with your wound care nurse, physician or surgeon to ensure HBOT is integrated alongside optimized pressure relief, nutrition, wound dressings and infection management.
HBOT sessions to restore wound bed oxygenation
You breathe 100% oxygen at 2.0 to 2.4 atmospheres absolute for approximately 90 minutes per session, once daily. Pressure ulcer protocols typically involve 30 to 40 sessions as an initial course, with wound healing progress assessed at completion. Transcutaneous oximetry (TcPO2) measurements confirm that treatment is reaching therapeutic tissue oxygen levels.
Healing monitoring and long-term prevention
We track wound area, depth, granulation tissue quality, peri-wound skin condition and infection markers throughout treatment. Following wound closure, we work with your care team to address the underlying risk factors — pressure relief, positioning, nutrition, moisture management — that prevent recurrence, which is common in patients with ongoing immobility or neurological conditions.
Frequently Asked Questions
Answers to the questions patients, families and wound care providers most often ask about HBOT for pressure ulcers.
Medicare may cover HBOT for pressure ulcers that meet the qualifying criteria for non-healing wounds: adequate arterial blood supply to the wound area (typically confirmed by ABI or TcPO2 testing), and failure to demonstrate measurable healing progress after 30 days of appropriate standard wound care. Stage 3 and Stage 4 pressure ulcers that meet these criteria are the most likely candidates for coverage. Our staff will assess your wound documentation and coordinate prior authorization with Medicare or your commercial insurer.
Non-healing pressure ulcer? Medicare coverage may be available — call us
Bay Area Hyperbarics provides HBOT for Stage 3 and Stage 4 pressure ulcers that have not responded to standard wound care. Our team coordinates with your wound care specialist, vascular surgeon or rehabilitation medicine physician to deliver HBOT as part of a comprehensive pressure ulcer management plan. Medicare coverage may be available for qualifying wounds.
